Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2004

View Archived Issues

Targeting macrophage NF-kappaB activity may improve arthritis in vivo

Risedronate found effective in osteoporotic women treated with gastric acid inhibitors

Lipid profile changes found with exemestane in breast cancer patients

Novel 5-HT6 receptor ligands designed by GSK scientists

Two series of MCH receptor antagonists developed at Neurocrine

Millennium presents new ALK5 inhibitors and their potential applications

Ono researchers develop novel chemokine CCR5 antagonists

New ZAP70 and Syk kinase inhibitors claimed by NeoGenesis

New beta-secretase inhibitors under evaluation at GSK

KuDOS and Maybridge collaborate to develop new PARP inhibitors

NeuroSearch scientists prepare and test new KCNQ channel modulators

Serotonin receptor agonists for treatment of ocular hypertension and glaucoma

Development of novel topoisomerase inhibitors for solid tumor therapy

Angelini to launch prulifloxacin in Italy

Pyrazine nucleosides target hepatitis C virus polymerase

Fast track status for doripenem for nosocomial pneumonia

Promising antifungal compound effective in vitro and in vivo

Kahalalide F enters phase II trials for severe psoriasis

Novel low molecular weight anti-HIV agents by Merck & Co.

Start-up of Merck Pharma GmbH

Nuvelo to gain worldwide rights to alfimeprase

Approvable letter for Nascobal Nasal Spray

Pivotal study compares Numax to Synagis for RSV

Maxim to close Ceplene treatment protocol and withdraw NDA

Axcan launches URSO Forte

Reata Discovery licenses novel anticancer compounds

MD-1100 enters phase I study for IBS

Treatment phase begins in pivotal TRIUMPH study of eculizumab for PNH

Sosei launches U.S. company targeting CNS disorders

Sucampo and Takeda enter collaboration and license agreement for lubiprostone

Antiinflammatory mechanism of ajulemic acid examined in vitro

Everolimus improves methotrexate efficacy in RA

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....